Artículos por temáticas

Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer's disease: a pilot randomized controlled trial

Suttanon P, Hill KD, Said CM, Williams SB, Byrne KN, LoGiudice D, Lautenschlager NT, Dodd KJ.

Clin Rehabil. 2013 May;27(5):427-38. doi: 10.1177/0269215512460877. Epub 2012 Nov 1.

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors

Bolea I, Gella A, Unzeta M.

J Neural Transm (Vienna). 2013 Jun;120(6):893-902. doi: 10.1007/s00702-012-0948-y. Epub 2012 Dec 13.

Dying other, dying self: creating culture and meaning in palliative healthcare

McCann CJ, Adames HY.

Palliat Support Care. 2013 Aug;11(4):289-93. doi: 10.1017/S1478951512000557. Epub 2012 Aug 1.

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C.

Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104.

[Cyclooxygenases, lipoxygenases, their targeted drugs and the prevention of Alzheimer's disease]

Shen JN, Xu LX, Wang R.

Yao Xue Xue Bao. 2013 Dec;48(12):1743-54.

Video prompting versus other instruction strategies for persons with Alzheimer's disease

Perilli V, Lancioni GE, Hoogeveen F, Caffó A, Singh N, O'Reilly M, Sigafoos J, Cassano G, Oliva D.

Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):393-402. doi: 10.1177/1533317513488913. Epub 2013 May 17.

The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors

Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, Gemma S.

Curr Top Med Chem. 2013;13(15):1787-807. doi: 10.2174/15680266113139990137.

Evaluation of the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer's patients with moderate cognitive impairment: a pilot study

Salotti P, De Sanctis B, Clementi A, Fernandez Ferreira M, De Silvestris T.

Aging Clin Exp Res. 2013 Aug;25(4):403-9. doi: 10.1007/s40520-013-0062-5. Epub 2013 Jun 13.

Trafficking in neurons: searching for new targets for Alzheimer's disease future therapies

Musardo S, Saraceno C, Pelucchi S, Marcello E.

Eur J Pharmacol. 2013 Nov 5;719(1-3):84-106. doi: 10.1016/j.ejphar.2013.07.019. Epub 2013 Jul 23.

Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial

Campbell NL, Dexter P, Perkins AJ, Gao S, Li L, Skaar TC, Frame A, Hendrie HC, Callahan CM, Boustani MA.

Trials. 2013 May 4;14:125. doi: 10.1186/1745-6215-14-125.

A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease

Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA.

Bioorg Med Chem. 2013 May 1;21(9):2434-50. doi: 10.1016/j.bmc.2013.02.017. Epub 2013 Feb 27.

From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors

Russo P, Frustaci A, Del Bufalo A, Fini M, Cesario A.

Curr Med Chem. 2013;20(8):976-83.

Mens sana in corpore sano revisited

Jeger RV.

Eur Heart J. 2013 Sep;34(33):2580-1. doi: 10.1093/eurheartj/eht244. Epub 2013 Jul 4.

Discovering new treatments for Alzheimer's disease by repurposing approved medications

Appleby BS, Cummings JL.

Curr Top Med Chem. 2013;13(18):2306-27. doi: 10.2174/15680266113136660162.

Targeting nascent soluble Aβ42 for potential Alzheimer drug development

Zhang M, Hausmann L, Song W.

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.